New data suggest that plasma soluble urokinase receptor (suPAR) might be a predictive biomarker and potential therapeutic target for acute kidney injury (AKI). However, many questions remain regarding the potential of suPAR to inform clinical decision making, identify patients for enrolment in clinical trials and add to the understanding of AKI pathogenesis.

中文翻译：

---

SuPAR：急性肾损伤的潜在预测生物标志物。

新数据表明，血浆可溶性尿激酶受体（suPAR）可能是急性肾损伤（AKI）的预测生物标志物和潜在治疗靶标。但是，关于suPAR可能为临床决策提供依据，确定要招募参加临床试验的患者以及加深对AKI发病机理的理解，仍然存在许多问题。